IPOT — Isracann Biosciences Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
Annual income statement for Isracann Biosciences, fiscal year end - May 31st, CAD millions except per share, conversion factor applied.
2018 May 31st | R2019 May 31st | 2020 May 31st | 2021 May 31st | 2022 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.17 | 0.063 | 0.14 | 0.076 | 0 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 8.53 | 5.66 | 23.8 | 25.6 | 3.3 |
| Operating Profit | -7.35 | -5.6 | -23.7 | -25.5 | -3.3 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -7.47 | -5.6 | -24 | -25.1 | -4.69 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.47 | -5.6 | -23.9 | -25.1 | -4.69 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -7.47 | -9.9 | -24.2 | -25.2 | -4.69 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.47 | -9.9 | -24.2 | -25.2 | -4.69 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.286 | -0.146 | -0.173 | -0.086 | -0.027 |